LVTX — LAVA Therapeutics NV Balance Sheet
0.000.00%
- $38.93m
- -$17.24m
- $11.98m
- 46
- 26
- 29
- 23
Annual balance sheet for LAVA Therapeutics NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 10-K | 10-K |
| Standards: | IFRS | IFRS | IFRS | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 15.8 | 133 | 133 | 95.6 | 76.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.48 | 0.734 | 3.25 | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 18.2 | 137 | 141 | 98.9 | 79.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.5 | 1.95 | 2.08 | 2.46 | 1.44 |
| Other Long Term Assets | |||||
| Total Assets | 20.5 | 139 | 143 | 102 | 80.8 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.33 | 11.2 | 22 | 14.9 | 18 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 12.9 | 20.9 | 57.4 | 50.3 | 53.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 7.62 | 118 | 86 | 51.4 | 27.7 |
| Total Liabilities & Shareholders' Equity | 20.5 | 139 | 143 | 102 | 80.8 |
| Total Common Shares Outstanding |